Michael F. Sarosdy - Concepedia

Author

Michael F. Sarosdy

The University of Texas Health Science Center at San Antonio

Also Known As

M F Sarosdy, M. F. Sarosdy, M. F.* Sarosdy, M.F Sarosdy, M.F. Sarosdy, MICHAEL F. SAROSDY, Michael F Sarosdy, Michael F. Sarosdy

107

Publications

10.5K

Citations

H-Index

Concepts

All Affiliations

The University of Texas Health Science Center at San Antonio Eastern Virginia Medical School West Virginia University University of Miami Alberta Cancer Foundation

About

Michael F. Sarosdy is an author at The University of Texas Health Science Center at San Antonio specializing in medicine, urology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	28	2.1K
2	Health Sciences	3	3	72
3	Engineering	1	1	21
4	Natural Sciences	1	1	15
5	Biomedical Engineering	1	1	21

Michael F. Sarosdy

Publications

10.2K

Citations

H-Index

Page 1

	Year	Citations
Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer H. Barton Grossman, Ronald B. Natale, Catherine M. Tangen, New England Journal of Medicine	2003	2.6K
MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A RANDOMIZED SOUTHWEST ONCOLOGY GROUP STUDY Donald L. Lamm, Brent A. Blumenstein, John D. Crissman, The Journal of Urology	2000	1.3K
A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. Patrick J. Loehrer, Lawrence H. Einhorn, Paul Elson, Journal of Clinical Oncology	1992	984
A Randomized Trial of Intravesical Doxorubicin and Immunotherapy with Bacille Calmette–Guérin for Transitional-Cell Carcinoma of the Bladder Donald L. Lamm, Brent A. Blumenstein, E. David Crawford, New England Journal of Medicine	1991	613
Surgical Factors Influence Bladder Cancer Outcomes: A Cooperative Group Report Harry W. Herr, James R. Faulkner, H. Barton Grossman, Journal of Clinical Oncology	2004	597
Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. Dean F. Bajorin, Michael F. Sarosdy, David G. Pfister, Journal of Clinical Oncology UrologyEtoposide DoseCancer EpidemiologyMedicineMultiinstitutional Study	1993	361
Prospective clinical trial of a human tumor cloning system. Daniel D. Von Hoff, Gary M. Clark, Brian J. Stogdill, PubMed Tumor BiologyTumoral PathologyTumor HeterogeneitySingle AgentTumor Growth	1983	339
Use of a New Tumor Marker, Urinary NMP22, in the Detection of Occult or Rapidly Recurring Transitional Cell Carcinoma of the Urinary Tract Following Surgical Treatment Mark S. Soloway, Joseph V. Briggman, Gennaro A. Carpinito, The Journal of Urology	1996	339
Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. Michael F. Sarosdy, Paul F. Schellhammer, Gary Bokinsky, PubMed	2002	273
Clinical Evaluation of a Multi-target Fluorescent in Situ Hybridization Assay for Detection of Bladder Cancer Michael F. Sarosdy, Paul F. Schellhammer, Gary Bokinsky, The Journal of Urology Tumor BiologyUrological ResearchUrologyOncologyTransitional Cell Carcinoma	2002	258

Page 1